Tofacitinib effectively treats patients with PMR as glucocorticoid does.
DISEASE, PMR, POLYMYALGIA RHEUMATICA
Patients with newly diagnosed PMR were randomized to the tofacitinib (5 mg BID) group and the glucocorticoids (Pred 15 mg/day, gradually tapered) group for 24 weeks. All PMR patients underwent clinical and laboratory examinations at 0, 4, 8, 12, 16, 20, and 24 weeks, and PMR-AS were calculated. At weeks 12 and 24, all patients in both groups had PMR-AS <10. PMR-AS, CRP, and ESR were all significantly decreased at weeks 12, and 24 in both groups. CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; PMR, polymyalgia rheumatica; PMR-AS, PMR activity disease score.